2Folprecht G, Lutz M P, Schoffski P,et al. Cetuximab and irinotecan/5-fluorouracil/folinic acidis a safe combination for the first line treatment of patients with epidermalgrowth factor receptor expressing metastatic colorectal carcinoma[J]. Ann Oncol 2006, 17(3) : 450-456.
3Tabernero J, Pfeiffer P, Cervantes A. Administration of cetux imab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more conveient alternative to weekly ad ministration[J]. Oncologist, 2008,13(2) :113-119.
4Jimenez P, Gomez G, Rodriguez B, et al. Acute acneiform eruption secondary to cetuximab with good response to metronidazole [J]. Actas Dermosifiliogr, 2007,98 (9) : 648-653.
5Lenz H J,Van Cutsem E, Khambata F S, et al. Multicenter phase Ⅱ and translational study of eetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluropyrimidines[J]. J Clin Oncol,2006,24(30) :4914-4921.
6Chung K Y, Shia J, Kemeny N E, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J]. J Clin Oncol,2005,23(9) :1803-1810.
7Aurelien R, Valerie B, Gerard M,et al. KRAS mutation signa ture in colorectal tumors significantly overlaps with the cetux imab response signature[J]. J Clin Oncol,2008,26(13) : 2228-2230.
二级参考文献6
1Jemal A, Tiwari R C, Murray T, et al. Cancer statistics, 2004 [J]. CA Cancer J Clin, 2004,54(1) :8-29.
2Garcia-Carbonero R, Supko J G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins[J]. Clin Cancer Res, 2002,8(2) : 641-661.
3Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients[J]. Cancer Chemother Pharmacol, 2000,34(3): 293--296.
4Hoff P M, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous 5 fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer. Results of arandomized phase Ⅲ study[J]. J Clin Oncol,2001. 19(8): 2282-2292.
5Carlini L Z, Meropol N J, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/Irinotecan[J].Clin Cancer Res, 2005.11(3): 1226-- 1236.
6Tewes M, Schleucher N, Achterrath W,et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase Ⅰ study[J].Ann Oncol, 2003, 14(10):1442-1448.
1Shah M A, Schwartz G K. Treatment of metastatic esophagus and gastric cancer[J]. Semin Oncol,2004,31(4): 574-587.
2Gupta D, Middleton L P, Whitaker M J, et al. Comparison of fluorescenee and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer[J]. Am J Clin Pathol, 2003,119(3): 381- 387.
3Kim M A, Lee H S, Lee H E, et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number[J]. BMC Cancer, 2008,8(10):1-6.
4Kimura M, Tsuda H, Morita D, et al. Aproposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c erbB-2 gene copy numbers in gastric carcinoma, based on correlation of chromogenic in situ hybridization and immunohistochemical measurements[J]. Virchows Arch, 2004, 445(3) : 255-262.
5Soulieres D, Senzer N N, Vokes E E, et al. Muhicenter phase Ⅱ study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck[J]. J Clin Oncol, 2004,22(1): 77-85.
6Kim GP, Sargent DJ, Mahoney MR, et al. Phase Ⅲ noninfefiori- ty trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced eolorectal carcinoma previ- ously treated with fluorouracil : N9841 [J]. J Clin Oncol, 2009, 27(17) : 2848 -2854.
7Kemeny N, Garay CA, Gurtler J, et al. Randomized multicenter phase Ⅱ trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracilfleucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer[J]. J Clin Oncol, 2004, 22(23): 4753-4761.
8Gholam D, Giacchetti S, Brezault-Bonnet C, et al. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouraeil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer[J]. Oncologist, 2006, 11(10): 1072-1080.
9Bitossi R, Sculli CM, Tampellini M, et al. Gemcitabine and pro- tracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients[J]. Anticancer Res, 2008, 28 (5B) : 3055 -3060.
10Ardavanis AS, Ioannidis GN, Orphanos GS, et al. Salvage treatment with single-agent capecitabine in patients with heavily pre treated advanced colorectal cancer [ J]. Anticancer Res, 2006, 26(2B) : 1669 - 1672.
